While screening for prostate cancer using the prostate-specific antigen blood test (PSA) and digital rectal examination (DRE) are effective available measures for early detection of disease, utilization of these services ranges from 0% to 15% in Africa [4, 7–10]. The gene discussed is KLK3; the disease is prostate cancer.